About us

BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) represents European small and medium-sized biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance, including small molecule antibiotics, biologics, products with a prophylaxis indication, and new technologies that include microbiome-based and phage-based therapies, immune targeting therapies, and anti-biofilm agents. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.


BOARD MEMBERS

· Florence Séjourné  ( bio ), President. Da Volterra (Paris, France)

· Marc Gitzinger  ( bio ), Vice-President.  BioVersys   (Basel, Switzerland)

· Holger Schmoll  ( bio ), Treasurer. AiCuris (Wuppertal, Germany)

· Mark Jones  ( bio ), Secretary. Basilea (Basel, Switzerland)

· Marc Lemonnier  ( bio ), Officer. Antabio (Toulouse, France)

· Marie Petit  (bio), Coordinator. marie.petit@beam-alliance.eu

BEAM ALLIANCE IN NUMBERS

Members

Employees

Product in the market

Products in preclinical research

Products in clinical development

Données cartographiques
Données cartographiques ©2018 Google, INEGI, ORION-ME
Données cartographiques Données cartographiques ©2018 Google, INEGI, ORION-ME
Données cartographiques ©2018 Google, INEGI, ORION-ME